CHICAGO (Reuters) – If Moderna Inc’s <MRNA.O> COVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk groups, the company’s chief executive told Reuters.
Moderna’s vaccine candidate – mRNA-1273 – is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus vaccine. As of Wednesday night, Moderna had enrolled 25,296 participants.
But the company may be able to declare victory early if it is able to show that people who got the vaccine fared much better in its trial that people who did not.
Vaccines must demonstrate they are at least 50% moreeffective than a placebo to be considered for approval. To provethat, government officials have said, at least 150 COVID-19infections must be recorded among trial participants with atleast twice as many occurring among the placebo group.
If a vaccine is especially effective, companies could havetheir answer sooner.
An independent safety board will take a first look at Moderna’s data as soon as a total of 53 people in the trial become infected with COVID-19. Moderna is projecting the interim analysis will occur in November, but it could come as early as October.
If most of the people who got sick got the placebo shot, that would indicate the vaccine was protecting those inoculated and could be enough evidence to seek U.S. regulatory approval for Emergency Use Authorization (EUA).
“If the interim readout is deemed by the independent safety committee as positive with 70 or 80 or 90% efficacy, we will indeed consider approval,” Stephane Bancel, Moderna’s chief executive officer, said in a telephone interview.
“At such a level of efficacy, if we get there, we can protect a lot of lives in the people at the highest risk, and so, we will consider filing for an EUA for a very limited population,” Bancel said.
He said the Food and Drug Administration will determine whether the benefit of the vaccine to a small group of high-risk individuals outweighs the risk of not having a full readout of safety data from all 30,000 study participants.
The two groups of high-risk individuals who might be covered in such an EUA would be healthcare workers and the elderly, Bancel said.
In a conference call with investors on Thursday, Bancel said he expects the company to file for an EUA in 2020, and for full FDA approval.
He told Reuters the company wants to gather more data on the safety of the vaccine in the study population over a period of several months before seeking full licensure.
Moderna released its study protocol on Thursday, making public details on how its vaccine will be evaluated. If the vaccine does not reach the efficacy mark after 53 cases, the data safety and monitoring board will take another interim look at the data after 106 cases, and a final look after 151 people in the trial become infected with the virus.
Public health officials have said that approving a vaccine for widespread use based on a small number of cases would not offer enough safety information to show how the vaccine would perform.
Moderna, which has never brought a vaccine to market, hasreceived nearly $1 billion from the U.S. government under itsOperation Warp Speed program. It has also struck a $1.5 billionsupply agreement with the United States.
On the call, the company said it is on track to deliver 500 million to 1 billion doses of the vaccine annually. In the United States, decisions about vaccine allocation will be made by the U.S. government, the company said.
Moderna also announced plans to start developing seasonal flu vaccines.
In a presentation to investors on Tuesday, Pfizer Inc <PFE.N> said the company has enrolled more than 29,000 people in its 44,000-volunteer trial to test an experimental COVID-19 vaccine the company is developing with German partner BioNTech <22UAy.F>.
Pfizer expects to have enough data to show whether the vaccine works by the end of October.
(Reporting by Julie Steenhuysen in Chicago and Manas Mishra in Bengaluru; Editing by Peter Henderson and Timothy Gardner)
